Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis-B vaccination: unresolved questions].

W Jilg1

  • 1Max-von-Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Universität München.

Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|June 9, 1992
PubMed
Summary

Hepatitis B vaccination offers lasting protection, with a 5-year booster sufficient for initial responders. Universal childhood vaccination is key to significantly reducing hepatitis B incidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time course of hepatitis E-specific antibodies in adults.

Journal of viral hepatitis·2016
Same author

Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2015
Same author

[Not Available].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2014
Same author

[Influenza].

Deutsche medizinische Wochenschrift (1946)·2013
Same author

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Infection·2011
Same author

[Vaccinations].

Deutsche medizinische Wochenschrift (1946)·2011

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Context:

  • Hepatitis B remains a significant global health concern.
  • Current vaccination strategies face challenges in optimizing long-term protection and addressing non-response.
  • Existing strategies targeting only risk groups have limited impact on overall hepatitis B incidence.

Purpose:

  • To review the current understanding of hepatitis B vaccine efficacy and safety.
  • To address unresolved issues including duration of protection, non-responders, and optimal vaccination strategies.
  • To evaluate the public health impact of different hepatitis B vaccination approaches.

Summary:

  • Recent evidence suggests hepatitis B vaccine protection duration exceeds initial assumptions, with a 5-year booster adequate for initial responders.
  • For non-responders, further vaccinations can be successful in over half of cases.
  • Universal childhood hepatitis B vaccination is essential for significantly reducing disease burden, as vaccinating only risk groups has shown minimal impact.

Impact:

  • Recommends a shift towards universal childhood hepatitis B vaccination for effective disease control.
  • Highlights the need for continued research into optimizing vaccination schedules and strategies for non-responders.
  • Emphasizes the long-term efficacy of hepatitis B vaccines and the importance of timely revaccination.

Related Experiment Videos